A S Magaret1, C Johnston, A Wald. 1. Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA. amag@u.washington.edu
Abstract
OBJECTIVES: We evaluated two methods to describe detection of herpes simplex virus (HSV) from the genital mucosa. METHODS: We assessed genital swabs from HSV-2 seropositive people participating in longitudinal studies of HSV DNA detection at the University of Washington Virology Research Clinic. We determined the length of observation period necessary to ensure some HSV detection for most individuals. We compared two measures to assess differences in shedding according to HIV status, the shedding rate ratio, defined as the proportion of total samples with detectable HSV in HIV-1 seropositive versus HIV-1 seronegative participant, and the ratio of "shedders", defined as the proportion of people with any shedding over the interval in HIV-1 seropositive versus HIV-1 seronegative people. RESULTS: While only 17% (51/308) of HSV-2 seropositive people shed on their first day on study, 77% (238/308) had some genital shedding over 30 days (any HSV DNA detected on genital swabs). Shedding rate ratios (SRR) for HIV-seropositive versus HIV-seronegative people varied from SRR = 1.42 using 10 samples to SRR = 1.35 using 50 samples. The ratio of "shedders" (RS) approached 1 as the observation period increased (RS = 1.13 using 10 samples to RS = 1.01 using 50 samples). In a hypothetical case, the ratio of "shedders" was shown to exceed 1 when shedding rates were equal. CONCLUSIONS: Most HSV-2 seropositive people shed HSV from the genital mucosa. Dichotomisation of people into "shedders" and "non-shedders" or "high" and "low" shedders yields inferences that depend upon sampling interval length. Overall shedding rates provide consistent measures regardless of the number of swabs collected.
OBJECTIVES: We evaluated two methods to describe detection of herpes simplex virus (HSV) from the genital mucosa. METHODS: We assessed genital swabs from HSV-2 seropositive people participating in longitudinal studies of HSV DNA detection at the University of Washington Virology Research Clinic. We determined the length of observation period necessary to ensure some HSV detection for most individuals. We compared two measures to assess differences in shedding according to HIV status, the shedding rate ratio, defined as the proportion of total samples with detectable HSV in HIV-1 seropositive versus HIV-1 seronegative participant, and the ratio of "shedders", defined as the proportion of people with any shedding over the interval in HIV-1 seropositive versus HIV-1 seronegative people. RESULTS: While only 17% (51/308) of HSV-2 seropositive people shed on their first day on study, 77% (238/308) had some genital shedding over 30 days (any HSV DNA detected on genital swabs). Shedding rate ratios (SRR) for HIV-seropositive versus HIV-seronegative people varied from SRR = 1.42 using 10 samples to SRR = 1.35 using 50 samples. The ratio of "shedders" (RS) approached 1 as the observation period increased (RS = 1.13 using 10 samples to RS = 1.01 using 50 samples). In a hypothetical case, the ratio of "shedders" was shown to exceed 1 when shedding rates were equal. CONCLUSIONS: Most HSV-2 seropositive people shed HSV from the genital mucosa. Dichotomisation of people into "shedders" and "non-shedders" or "high" and "low" shedders yields inferences that depend upon sampling interval length. Overall shedding rates provide consistent measures regardless of the number of swabs collected.
Authors: Guy de Bruyn; Mauricio Vargas-Cortez; Terri Warren; Stephen K Tyring; Kenneth H Fife; Jacob Lalezari; Rebecca C Brady; Mohsen Shahmanesh; George Kinghorn; Karl R Beutner; Rajul Patel; Margaret A Drehobl; Patrick Horner; Terrance O Kurtz; Sharon McDermott; Anna Wald; Lawrence Corey Journal: Vaccine Date: 2005-09-21 Impact factor: 3.641
Authors: Catherine M Crespi; William G Cumberland; Anna Wald; Lawrence Corey; Sally Blower Journal: Sex Transm Infect Date: 2007-05-02 Impact factor: 3.519
Authors: N Nagot; A Ouedraogo; I Konate; H A Weiss; V Foulongne; M C Defer; A Sanon; P Becquart; M Segondy; A Sawadogo; P Van de Perre; P Mayaud Journal: J Infect Dis Date: 2008-07-15 Impact factor: 5.226
Authors: P Mayaud; N Nagot; I Konaté; A Ouedraogo; H A Weiss; V Foulongne; M-C Defer; A Sawadogo; M Segondy; P Van de Perre Journal: Sex Transm Infect Date: 2008-07-02 Impact factor: 3.519
Authors: Nicolas Nagot; Abdoulaye Ouédraogo; Vincent Foulongne; Issouf Konaté; Helen A Weiss; Laurence Vergne; Marie-Christine Defer; Didier Djagbaré; Anselme Sanon; Jean-Baptiste Andonaba; Pierre Becquart; Michel Segondy; Roselyne Vallo; Adrien Sawadogo; Philippe Van de Perre; Philippe Mayaud Journal: N Engl J Med Date: 2007-02-22 Impact factor: 91.245
Authors: Tajanna Stinn; Steve Kuntz; Dana Varon; Meei-Li Huang; Stacy Selke; Samuel Njikan; Emily S Ford; Joan Dragavon; Robert W Coombs; Christine Johnston; Marta E Bull Journal: J Virol Date: 2020-12-09 Impact factor: 5.103
Authors: Andrew Mujugira; Meei-Li Huang; Stacy Selke; Linda Drolette; Amalia S Magaret; Anna Wald Journal: Sex Transm Dis Date: 2015-12 Impact factor: 2.830